ROCKVILLE, Md., Nov. 10, 2020 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced that two oral presentations will be
presented at the American Academy Ophthalmology (AAO) 2020 Annual
Meeting, taking place November 13-15,
2020 in a virtual format.
The first presentation will feature data from the RGX-314 Phase
I/II subretinal trial for the treatment of wet age-related macular
degeneration (wet AMD). Details are as follows:
Title: Update on the Subretinal RGX-314 Gene Therapy
Phase 1/2a Study for the Treatment of Neovascular AMD
Presenter: Dante Pieramici,
M.D., Director, California Retina Research Foundation and Partner,
California Retina Consultants
Date/time: Available on-demand
Session title: RET07 – Gene- and Cell-Based
Therapies
The second presentation will include data from preclinical
studies of suprachoroidal delivery of RGX-314. Details are as
follows:
Title: Viral and Nonviral Suprachoroidal Ocular Gene
Transfer
Presenter: Peter A Campochiaro, M.D., Director, Retinal Cell
and Molecular Laboratory, Professor of Ophthalmology, The Wilmer
Eye Institute, Johns Hopkins University School
of Medicine
Date/time: Friday, November 13,
2020 at 12:36pm PST
Session title: RET07V – Gene- and Cell-Based
Therapies
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting-301169240.html
SOURCE REGENXBIO Inc.